Fresenius Kabi’s first-to-market generic version of Foscavir® (foscarnet sodium injection) is now available.
Foscarnet sodium injection is indicated to treat cytomegalovirus (CMV) retinitis in patients with AIDS. Combination therapy of Foscarnet Sodium Injection and ganciclovir is indicated for patients who have relapsed after monotherapy with either drug. It is also indicated for the treatment of acyclovir-resistant mucocutaneous herpes simplex virus (HSV) infections in immunocompromised patients.
The safety and efficacy of Foscarnet Sodium Injection have not been established for treatment of other CMV infections (ie, pneumonitis, gastroenteritis), other HSV infections (ie, retinitis, encephalitis), congenital or neonatal CMV or HSV disease, or in nonimmunocompromised individuals.
Fresenius Kabi’s Foscarnet Sodium Injection is supplied in 250mL bottles containing 6000mg of foscarnet sodium (24mg/mL).
“We’re pleased to offer this first-to-market generic for Foscavir in the United States, an important treatment for immune-compromised patients,” said John Ducker, president and CEO of Fresenius Kabi USA.
Fresenius Kabi Introduces First-Ever Generic for Foscavir® (Foscarnet Sodium) Injection. [press release]. Lake Zurich, IL: Fresenius Kabi; March 15, 2021.
This article originally appeared on MPR